Your search for non small cell lung cancer returned 54 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Da Hee Han, PharmD remove
Older than 2 years remove

Your search for non small cell lung cancer returned 54 results

Sort Results:

Relevant Recent
News

Keytruda Gains Expanded Monotherapy Indication for First-Line Treatment of NSCLC

Merck announced that the Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
News

Keytruda Gains First Gynecologic Cancer Indication

Data showed ORR was 14.3% (95% CI, 7.4-24.1) with 2.6% achieving complete response and 11.7% achieving partial response. Of the 11 responders, median DOR was not yet reached at the time of analysis; 91% of patients, however, had a DOR of ≥6 months.